On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD.

ReST Therapeutics’  project is to develop a proprietary drug candidate for the treatment of  Post-Traumatic Syndrome and Alzheimer’s disease. The molecule, FENM®, initially developed as a biomarker of the brain receptor NMDA* has given very promising results in preclinical trials conducted simultaneously in France (with the University of Montpellier and the Ecole Normale Supérieure de Paris-PSL) and in the United States (with Columbia University).

“Obtaining this patent on our key therapeutic target in the US which is the main market for our application reinforces our commitment on finding a cure for PTSD at the time where we are reaching the clinical phase of our development with the FIH for FENM being planned in 2023. It allows us to look forward with serenity to the next fundraising that we will make at this time to implement the clinical demonstration on PTSD,” said Gilles Rubinstenn, Founding President of ReST Therapeutics. 

 * NMDA receptors are ionotropic receptors essential to the memory and synaptic plasticity.